Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

A Phase 2, Double-Blind, Placebo-Controlled Randomized Trial Assessing the Efficacy of ABT-436, a Novel V1b Receptor Antagonist, for Alcohol Dependence.

Ryan ML, Falk DE, Fertig JB, Rendenbach-Mueller B, Katz DA, Tracy KA, Strain EC, Dunn KE, Kampman K, Mahoney E, Ciraulo DA, Sickles-Colaneri L, Ait-Daoud N, Johnson BA, Ransom J, Scott C, Koob GF, Litten RZ.

Neuropsychopharmacology. 2017 Apr;42(5):1012-1023. doi: 10.1038/npp.2016.214. Epub 2016 Sep 23.

2.

Single-Dose Interaction Study of the Arginine Vasopressin Type 1B Receptor Antagonist ABT-436 and Alcohol in Moderate Alcohol Drinkers.

Katz DA, Locke C, Liu W, Zhang J, Achari R, Wesnes KA, Tracy KA.

Alcohol Clin Exp Res. 2016 Apr;40(4):838-45. doi: 10.1111/acer.12996. Epub 2016 Mar 10.

PMID:
26969417
3.

The safety and efficacy of baclofen to reduce alcohol use in veterans with chronic hepatitis C: a randomized controlled trial.

Hauser P, Fuller B, Ho SB, Thuras P, Kern S, Dieperink E.

Addiction. 2017 Jul;112(7):1173-1183. doi: 10.1111/add.13787. Epub 2017 Apr 2.

PMID:
28192622
4.

Clinical safety and hypothalamic-pituitary-adrenal axis effects of the arginine vasopressin type 1B receptor antagonist ABT-436.

Katz DA, Liu W, Locke C, Dutta S, Tracy KA.

Psychopharmacology (Berl). 2016 Jan;233(1):71-81. doi: 10.1007/s00213-015-4089-5. Epub 2015 Sep 26.

PMID:
26407603
5.

Hypothalamic-pituitary-adrenal axis and depression symptom effects of an arginine vasopressin type 1B receptor antagonist in a one-week randomized Phase 1b trial.

Katz DA, Locke C, Greco N, Liu W, Tracy KA.

Brain Behav. 2017 Feb 9;7(3):e00628. doi: 10.1002/brb3.628. eCollection 2017 Mar.

6.

A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients.

Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, Brunette MF, Kampman K, A Tompkins D, Stout R; NCIG 002 Study Group.

Alcohol Clin Exp Res. 2012 Aug;36(8):1421-30. doi: 10.1111/j.1530-0277.2011.01716.x. Epub 2012 Feb 10.

7.

Efficacy and safety of baclofen for alcohol dependence: a randomized, double-blind, placebo-controlled trial.

Garbutt JC, Kampov-Polevoy AB, Gallop R, Kalka-Juhl L, Flannery BA.

Alcohol Clin Exp Res. 2010 Nov;34(11):1849-57. doi: 10.1111/j.1530-0277.2010.01273.x.

8.

A pilot double-blind treatment trial of memantine for alcohol dependence.

Evans SM, Levin FR, Brooks DJ, Garawi F.

Alcohol Clin Exp Res. 2007 May;31(5):775-82. Epub 2007 Mar 22.

PMID:
17378918
9.

A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence.

Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, Scott C, Stout R; NCIG (National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group) Study Group.

J Addict Med. 2013 Jul-Aug;7(4):277-86. doi: 10.1097/ADM.0b013e31829623f4.

10.

Mecamylamine treatment for alcohol dependence: a randomized controlled trial.

Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH.

Addiction. 2018 Jan;113(1):6-14. doi: 10.1111/add.13943. Epub 2017 Oct 12.

11.

Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study.

Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME.

Arch Gen Psychiatry. 2005 Jan;62(1):37-45.

PMID:
15630071
12.

A phase 2, placebo-controlled study of the opioid receptor antagonist LY2196044 for the treatment of alcohol dependence.

Wong CJ, Witcher J, Mallinckrodt C, Dean RA, Anton RF, Chen Y, Fijal BA, Ouyang H, Dharia S, Sundseth SS, Schuh KJ, Kinon BJ.

Alcohol Clin Exp Res. 2014 Feb;38(2):511-20. doi: 10.1111/acer.12257. Epub 2013 Sep 6.

PMID:
24010675
13.

Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial Assessing Efficacy and Safety.

Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, Rosenthal RN, Dunn KE, Strain EC, Ray L, Shoptaw S, Ait-Daoud Tiouririne N, Gunderson EW, Ransom J, Scott C, Leggio L, Caras S, Mason BJ, Litten RZ; National Institute on Alcohol Abuse and Alcoholism Clinical Investigations Group (NCIG) Study Group.

Alcohol Clin Exp Res. 2019 Jan;43(1):158-169. doi: 10.1111/acer.13917. Epub 2018 Dec 9.

PMID:
30403402
14.
15.

Proof-of-Concept Study to Assess the Nociceptin Receptor Antagonist LY2940094 as a New Treatment for Alcohol Dependence.

Post A, Smart TS, Jackson K, Mann J, Mohs R, Rorick-Kehn L, Statnick M, Anton R, O'Malley SS, Wong CJ.

Alcohol Clin Exp Res. 2016 Sep;40(9):1935-44. doi: 10.1111/acer.13147. Epub 2016 Jul 20.

PMID:
27435979
16.

Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.

Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E.

Alcohol Alcohol. 2003 Mar-Apr;38(2):135-41.

PMID:
12634260
17.

Naltrexone vs Placebo for the Treatment of Alcohol Dependence: A Randomized Clinical Trial.

Oslin DW, Leong SH, Lynch KG, Berrettini W, O'Brien CP, Gordon AJ, Rukstalis M.

JAMA Psychiatry. 2015 May;72(5):430-7. doi: 10.1001/jamapsychiatry.2014.3053.

PMID:
25760804
18.

Association of the Sweet-Liking Phenotype and Craving for Alcohol With the Response to Naltrexone Treatment in Alcohol Dependence: A Randomized Clinical Trial.

Garbutt JC, Kampov-Polevoy AB, Kalka-Juhl LS, Gallop RJ.

JAMA Psychiatry. 2016 Oct 1;73(10):1056-1063. doi: 10.1001/jamapsychiatry.2016.2157.

PMID:
27627782
19.

Topiramate for treating alcohol dependence: a randomized controlled trial.

Johnson BA, Rosenthal N, Capece JA, Wiegand F, Mao L, Beyers K, McKay A, Ait-Daoud N, Anton RF, Ciraulo DA, Kranzler HR, Mann K, O'Malley SS, Swift RM; Topiramate for Alcoholism Advisory Board; Topiramate for Alcoholism Study Group.

JAMA. 2007 Oct 10;298(14):1641-51.

PMID:
17925516
20.

A pilot trial of prazosin, an alpha-1 adrenergic antagonist, for comorbid alcohol dependence and posttraumatic stress disorder.

Simpson TL, Malte CA, Dietel B, Tell D, Pocock I, Lyons R, Varon D, Raskind M, Saxon AJ.

Alcohol Clin Exp Res. 2015 May;39(5):808-17. doi: 10.1111/acer.12703. Epub 2015 Apr 1.

Supplemental Content

Support Center